Novel Survivin Inhibitor YM155 elicits Cytotoxicity in Glioblastoma Cell Lines with Normal or Deficiency DNA-Dependent Protein Kinase Activity

Pediatric glioblastoma is a malignant disease with an extremely poor clinical outcome. Patients usually suffer from resistance to radiation therapy, so targeted drug treatment may be a new possibility for glioblastoma therapy. Survivin is also overexpressed in glioblastoma. YM155, a novel small-mole...

Full description

Bibliographic Details

Published in:	Pediatrics and Neonatology
Main Authors:	Pei Chun Lai, Shu Huey Chen, Shang Hsien Yang, Chuan Chu Cheng, Ted H. Chiu, Yen Ta Huang
Format:	Article
Language:	English
Published:	Elsevier 2012-06-01
Subjects:	glioblastoma DNA-dependent protein kinase securin surviving YM155
Online Access:	http://www.sciencedirect.com/science/article/pii/S1875957212000587